Release Date: July 29, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Ionis Pharmaceuticals Inc IONS achieved a significant milestone with the FDA approval of TRYNGOLZA, the first and only medicine to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia.
- The company is experiencing strong commercial momentum with TRYNGOLZA and DAWNZERA, with TRYNGOLZA prescriptions starting on the day of approval.
- Ionis Pharmaceuticals Inc (IONS) is advancing its leadership in neurological diseases with the anticipated launch of Zilganerse, positioned as the first disease-modifying treatment for Alexander's disease.
- The company reported strong financial results with significant year-over-year revenue growth of 56% in the second quarter and 69% in the first half of the year.
- Ionis Pharmaceuticals Inc (IONS) maintains a robust pipeline with promising wholly-owned and partnered programs, including Bepirovirsen for chronic hepatitis B, which is on track for a global launch this year.
Negative Points
- The company faced a setback with the cardio transform Phase 3 study for eplontersen in ATTR cardiomyopathy, which did not meet the primary efficacy endpoint in the overall population.
- There are challenges in gaining payer coverage for TRYNGOLZA, with most early coverage being through medical exceptions.
- The launch of TRYNGOLZA for severe hypertriglyceridemia is expected to be a gradual build, requiring time to educate healthcare providers and patients.
- Ionis Pharmaceuticals Inc (IONS) anticipates increased operating expenses in 2026, driven by commercialization efforts and pipeline advancements.
- The company faces potential pressure on achieving cash flow breakeven by 2028 if certain pipeline programs, like pelacarsen, do not meet expectations.
Q & A Highlights
Q: Can you elaborate on the early adoption of TRYNGOLZA and the process for prescription coverage?
A: Kyle Jenne, Executive Vice President - Commercial, explained that early prescribers of TRYNGOLZA are often those who previously treated FCS patients. The process time for prescription coverage is still early to detail, but initial payer interactions are encouraging. Coverage is expected to improve through medical exceptions initially, with broader coverage anticipated as the year progresses.
Q: What are you seeing in terms of reimbursement for TRYNGOLZA, especially for patients with triglycerides over 500 versus over 880?
A: Kyle Jenne noted that reimbursement aligns with the label, which includes patients with triglycerides over 500 without limiting those over 880. Early approvals reflect this, and while prior authorizations are needed, the process is consistent with expectations.
Q: Are SHTG patients already on lipid-lowering drugs switching to TRYNGOLZA, or is it being added to their treatment?
A: Kyle Jenne stated that most SHTG patients are on background therapies like fibrates or omega-3s, and TRYNGOLZA is being added to these treatments. The drug's profile, including its monthly subcutaneous administration, is well-received, and there are no significant concerns about elevated liver fat.
Q: How has the recent pelacarsen data affected your outlook for TRYNGOLZA, and what is your confidence in the Horizon trial?
A: Brett Monia, CEO, expressed confidence in TRYNGOLZA as a best-in-class medicine for SHTG, with no concerns about competition. The Horizon trial is expected to show positive results, and any impact on financial guidance would be minimal.
Q: What are the expectations for the upcoming ESC meeting regarding ION 775 data, and what is the path to market for this program?
A: Holly Kordasiewicz, Chief Development Officer, mentioned that the ESC meeting will present year-long safety and efficacy data for ION 775. The program is in Phase 2b, and while timelines are not disclosed, the focus is on leveraging previous learnings to accelerate development.
Q: How is the early momentum of the SHTG launch tracking with internal expectations, and what is the regulatory path for monotherapy in cardiomyopathy?
A: Brett Monia stated that the SHTG launch is meeting internal expectations, with operational aspects like drug availability and payer engagement progressing well. For cardiomyopathy, AstraZeneca is reviewing data, and the ESC presentation will provide further insights.
Q: Is there an initial pent-up demand for TRYNGOLZA in SHTG, and what are the main competitors for DAWNZERA?
A: Kyle Jenne explained that the SHTG launch is expected to build gradually as awareness and payer access improve. DAWNZERA is competing in a switch market, with positive feedback from physicians leading to increased adoption.
Q: How does the lack of a dedicated ICD-10 code for SHTG affect TRYNGOLZA reimbursement, and what is the purpose of the meta-analysis at ESC?
A: Kyle Jenne acknowledged the challenge of not having a dedicated ICD-10 code but noted that reimbursement can still be achieved through medical history and prior authorizations. Holly Kordasiewicz added that the meta-analysis at ESC will compare silencer class data, including monotherapy and combination studies.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
